Search

Your search keyword '"Cannillo, Margherita"' showing total 22 results
Start Over Author "Cannillo, Margherita"
22 results on '"Cannillo, Margherita"'

3. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis

Author

D'Ascenzo, Fabrizio, Cerrato, Enrico, Calcagno, Andrea, Grossomarra, Walter, Ballocca, Flavia, Omedè, Pierluigi, Montefusco, Antonio, Veglia, Simona, Barbero, Umberto, Gili, Sebastiano, Cannillo, Margherita, Pianelli, Martina, Mistretta, Elisa, Raviola, Alessio, Salera, Davide, Garabello, Domenica, Mancone, Massimo, Estrada, Vicente, Escaned, Javier, De Marie, Daniela, Abbate, Antonio, Bonora, Stefano, Zoccai, Giuseppe Biondi, Moretti, Claudio, and Gaita, Fiorenzo

Published
2015
Full Text
View/download PDF

6. Incremental prognostic value of myocardial neuroadrenergic damage in patients with chronic congestive heart failure: An iodine-123 meta-iodobenzylguanidine scintigraphy study

Author

Spinnler Maria Teresa, Scrima Giovanni, Dellavesa Pierfranco, Gambino Alfonso, Bertuccio Giovanni, Maffè Stefano, Canavese Giacomo, Marcassa Claudio, Campini Riccardo, Paffoni Paola, Parravicini Umberto, and Cannillo Margherita

Subjects
Adult, Male, medicine.medical_specialty, Disease, 030204 cardiovascular system & hematology, Scintigraphy, Risk Assessment, 030218 nuclear medicine & medical imaging, Sudden cardiac death, Iodine Radioisotopes, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Internal medicine, Iodine-123, medicine, Humans, Radiology, Nuclear Medicine and imaging, In patient, Radionuclide Imaging, Aged, Retrospective Studies, Aged, 80 and over, Heart Failure, Ejection fraction, medicine.diagnostic_test, business.industry, Patient Selection, Middle Aged, Prognosis, medicine.disease, Defibrillators, Implantable, 3-Iodobenzylguanidine, Heart failure, Chronic Disease, Cardiology, Female, Radiopharmaceuticals, Cardiology and Cardiovascular Medicine, business, Mace
Abstract

ICD in primary prevention reduced mortality in patients with heart failure (HF); however, in about 80% of the ICD recipients an event requiring a device intervention will never occur. Thus, a reliable screening test included in a multiparametric approach to appropriately select patients to ICD implantation is increasingly required. Aim of the work was to assess if the Iodine-123 Meta-Iodobenzylguanidine scintigraphy (123I-mIBG) could be useful to identify patients with HF who would not benefit from the ICD implantation because at low risk of arrhythmias. This is a retrospective multicentre study on patients undergoing 123I-mIBG from February 2012 to December 2015. Inclusion criteria where: age ≥ 18 years old, LVEF ≤ 35% with idiopathic or ischemic heart disease, no previous malignant ventricular arrhythmias. Patients were divided in two groups based on of late H/M < or ≥ 1.60 on 123I-mIBG. Primary end-point was occurrence of malignant arrhythmias. Secondary end-point was occurrence of cardiac death and hospitalization for worsening HF. MACE were mortality and malignant arrhythmias. Eighty-one patients were enrolled (mean age: 69 years). On 123I-mIBG, 54 patients had late H/M

Published
2018
Full Text
View/download PDF

7. HEART FAILURE HOSPITALIZATION RATE REDUCTION DURING COVID-19 PANDEMIC

Author

D’Amato, Andrea, primary, Severino, Paolo, additional, Saglietto, Andrea, additional, D’Ascenzo, Fabrizio, additional, Marini, Claudia, additional, Schiavone, Marco, additional, Ghionzoli, Nicolò, additional, Pirrotta, Filippo, additional, Troiano, Francesca, additional, Cannillo, Margherita, additional, Mennuni, Marco, additional, Rognoni, Andrea, additional, Rametta, Francesco, additional, Galluzzo, Alessandro, additional, Agnes, Gianluca, additional, Infusino, Fabio, additional, Pucci, Mariateresa, additional, Lavalle, Carlo, additional, Cacciotti, Luca, additional, Mather, Paul, additional, Marra, Walter Grosso, additional, Ugo, Fabrizio, additional, Forleo, Giovanni, additional, Viecca, Maurizio, additional, Morici, Nuccia, additional, Patti, Giuseppe, additional, De Ferrari, Gaetano Maria, additional, Palazzuoli, Alberto, additional, Mancone, Massimo, additional, and Fedele, Francesco, additional

Published
2021
Full Text
View/download PDF

12. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak

Author

Severino, Paolo, primary, D'Amato, Andrea, additional, Saglietto, Andrea, additional, D'Ascenzo, Fabrizio, additional, Marini, Claudia, additional, Schiavone, Marco, additional, Ghionzoli, Nicolò, additional, Pirrotta, Filippo, additional, Troiano, Francesca, additional, Cannillo, Margherita, additional, Mennuni, Marco, additional, Rognoni, Andrea, additional, Rametta, Francesco, additional, Galluzzo, Alessandro, additional, Agnes, Gianluca, additional, Infusino, Fabio, additional, Pucci, Mariateresa, additional, Lavalle, Carlo, additional, Cacciotti, Luca, additional, Mather, Paul J., additional, Grosso Marra, Walter, additional, Ugo, Fabrizio, additional, Forleo, Giovanni, additional, Viecca, Maurizio, additional, Morici, Nuccia, additional, Patti, Giuseppe, additional, De Ferrari, Gaetano M., additional, Palazzuoli, Alberto, additional, Mancone, Massimo, additional, and Fedele, Francesco, additional

Published
2020
Full Text
View/download PDF

14. Prevalence and predictors of long corrected QT interval in HIV-positive patients

Author

Gili, Sebastiano, primary, Mancone, Massimo, additional, Ballocca, Flavia, additional, Grosso Marra, Walter, additional, Calcagno, Andrea, additional, D’Ettorre, Gabriella, additional, Cannillo, Margherita, additional, D’Ascenzo, Fabrizio, additional, Orofino, Giancarlo, additional, Marruncheddu, Laura, additional, Lonni, Enrica, additional, Cinque, Alessandra, additional, Vullo, Francesco, additional, Ceccarelli, Giancarlo, additional, Vilardi, Ilaria, additional, Sardella, Gennaro, additional, Vullo, Vincenzo, additional, Moretti, Claudio, additional, Fedele, Francesco, additional, Bonora, Stefano, additional, and Gaita, Fiorenzo, additional

Published
2017
Full Text
View/download PDF

17. Choosing the best first line oral drug agent in patients with pulmonary hypertension: Evidence from a network meta-analysis

Author

Biondi-Zoccai, Giuseppe, D'Ascenzo, Fabrizio, Cannillo, Margherita, Welton, Nicky J., Marra, Walter Grosso, Omedè, Pierluigi, Libertucci, Daniela, Fusaro, Enrico, Capriolo, Michele, Perversi, Jacopo, Fedele, Francesco, Frati, Giacomo, Mancone, Massimo, DiNicolantonio, James J., Vizza, Carmine Dario, Moretti, Claudio, and Gaita, Fiorenzo

Published
2013
Full Text
View/download PDF

18. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis

Author

Gili, Sebastiano, primary, Grosso Marra, Walter, additional, D'Ascenzo, Fabrizio, additional, Lonni, Enrica, additional, Calcagno, Andrea, additional, Cannillo, Margherita, additional, Ballocca, Flavia, additional, Cerrato, Enrico, additional, Pianelli, Martina, additional, Barbero, Umberto, additional, Mancone, Massimo, additional, DiNicolantonio, James J., additional, Lavie, Carl J., additional, Omedè, Pierluigi, additional, Montefusco, Antonio, additional, Bonora, Stefano, additional, Gasparini, Mauro, additional, Biondi-Zoccai, Giuseppe, additional, Moretti, Claudio, additional, and Gaita, Fiorenzo, additional

Published
2016
Full Text
View/download PDF

19. Heart failure in patients with human immunodeficiency virus

Author

Cannillo, Margherita, primary, D’Ascenzo, Fabrizio, additional, Grosso Marra, Walter, additional, Cerrato, Enrico, additional, Calcagno, Andrea, additional, Omedè, Pierluigi, additional, Bonora, Stefano, additional, Mancone, Massimo, additional, Vizza, Dario, additional, DiNicolantonio, James J., additional, Pianelli, Martina, additional, Barbero, Umberto, additional, Gili, Sebastiano, additional, Annone, Umberto, additional, Raviola, Alessio, additional, Salera, Davide, additional, Mistretta, Elisa, additional, Vilardi, Ilaria, additional, Colaci, Chiara, additional, Abbate, Antonio, additional, Zoccai, Giuseppe Biondi, additional, Moretti, Claudio, additional, and Gaita, Fiorenzo, additional

Published
2015
Full Text
View/download PDF

21. HEART FAILURE HOSPITALIZATION RATE REDUCTION DURING COVID-19 PANDEMIC.

Author

D'Amato, Andrea, Severino, Paolo, Saglietto, Andrea, D'Ascenzo, Fabrizio, Marini, Claudia, Schiavone, Marco, Ghionzoli, Nicolò, Pirrotta, Filippo, Troiano, Francesca, Cannillo, Margherita, Mennuni, Marco, Rognoni, Andrea, Rametta, Francesco, Galluzzo, Alessandro, Agnes, Gianluca, Infusino, Fabio, Pucci, Mariateresa, Lavalle, Carlo, Cacciotti, Luca, and Mather, Paul

Subjects
*COVID-19 pandemic, *HEART failure, *HOSPITAL care
Published
2021
Full Text
View/download PDF

22. [ANMCO Position paper: Amyloidosis for the clinical cardiologist. A "clinical primer" from the ANMCO Rare Disease Working Group].

Author

Chimenti C, Grego S, Di Fusco S, De Luca L, Caldarola P, Cannillo M, Cipriani M, Di Lenarda A, Donato D, Leone S, Limongelli G, Navazio A, Riccio C, Valente S, Gulizia MM, Gabrielli D, Oliva F, and Colivicchi F

Subjects
Humans, Prealbumin therapeutic use, Amyloid therapeutic use, Rare Diseases, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial genetics, Cardiologists
Abstract

Cardiac amyloidosis, in the three forms of immunoglobulin light chain (AL), transthyretin (ATTR) wild type (ATTRwt) and mutated (ATTRv) amyloidosis, is an increasingly known and recognized disease in the cardiovascular setting. The first stage of the patient's journey is the clinical suspicion of the disease, which is placed, in presence of a hypertrophic phenotype, by the identification of red flags, both extracardiac and cardiac clues whose presence increase the probability of being faced with a patient with this disease. The second stage is represented by diagnosis, which occurs with certainty through the identification of amyloid substance in cardiac tissue. This stage is spotted in wo parts, i.e. disease confirmation and disease etiology definition (AL vs ATTRwt vs ATTRv). However, it is possible in some selected cases to make a diagnosis of ATTR without the need for tissue assessment, in presence of a positive grade 2-3 bisphosphonate scintigraphy and absence of monoclonal component. Once the diagnosis has been made, the third stage is the assessment of prognosis, the fourth is the patient therapy pathway and fifth is the follow-up plan. Prognosis evaluation is based on different staging systems at the onset of the disease, whose applicability in the era of new effective therapies is still to be defined. To date, the transthyretin tetramer stabilizer tafamidis is the only approved treatment for both wild-type and mutant ATTR cardiomyopathy without polyneuropathy, while ATTRv with associated neuropathy can benefit from treatment with patisiran, an inhibitor of hepatic protein synthesis. Therapies for complications and comorbidities, must be addressed individually, due to the lack of specific clinical trials on this category of patients. In fact, it is important to take into consideration the risks linked to the use of some drugs due to the infiltration of the conduction tissue by the amyloid substance, which increases the risk of bradycardia and heart blocks, the tendency towards hypotension and the increased thromboembolic risk. It is also essential to follow the course of the disease and the efficacy of the treatment in affected patients with a standardized follow-up, and to identify early the signs/symptoms of the disease in asymptomatic TTR mutation carriers.This ANMCO position paper on amyloidosis aims to provide the clinical cardiologist with a practical summary of the disease, to accompany the patient with amyloidosis in the various stages of his journey.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results